Elias Harold K, Bryder David, Park Christopher Y
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Semin Hematol. 2017 Jan;54(1):4-11. doi: 10.1053/j.seminhematol.2016.11.002. Epub 2016 Nov 20.
Although hematopoietic stem cells (HSCs) have traditionally been thought to possess the ability to give rise to all the mature cell types in the hematopoietic system, this conception of hematopoiesis was based on evaluation of hematopoietic output from large numbers of HSCs using transplantation models. More recent studies evaluating HSCs at the clonal or near-clonal level, both in transplantation studies and during in situ hematopoiesis, have established that individual HSCs can exhibit lineage bias, giving rise to myeloid-biased, lymphoid-biased, or more balanced differentiation, with the proportion of myeloid-biased HSCs increasing with age. This age-associated shift in lineage potential is associated with decreased cellular immunity and increased incidence of diseases with prominent inflammatory components including atherosclerosis, autoimmunity, neurodegenerative disease, and carcinogenesis. Understanding the molecular mechanisms that regulate this shift in linage bias therefore represents an important area of investigation in numerous human diseases. In this review, we summarize our current understanding of the cell-intrinsic (autonomous) and cell-extrinsic factors that regulate HSC lineage fate bias during aging. In addition, we have attempted to bring attention to important caveats and unanswered questions related to the issue of HSC lineage bias to encourage explorations of these important lines of inquiry. Ultimately, we expect a comprehensive understanding of HSC lineage bias during aging to have important implications for human health, since strategies to alter lineage bias in old HSCs not only has the potential to restore immune function in the elderly, but also to reduce the incidence of inflammation-associated diseases, many for which there is a current unmet need for novel and more effective treatments.
尽管传统上认为造血干细胞(HSC)具有产生造血系统中所有成熟细胞类型的能力,但这种造血概念是基于使用移植模型对大量造血干细胞的造血输出进行评估得出的。最近在移植研究和原位造血过程中对克隆或近克隆水平的造血干细胞进行评估的研究表明,单个造血干细胞可表现出谱系偏向,产生髓系偏向、淋巴系偏向或更平衡的分化,其中髓系偏向的造血干细胞比例随年龄增长而增加。这种与年龄相关的谱系潜能转变与细胞免疫功能下降以及包括动脉粥样硬化、自身免疫、神经退行性疾病和癌症发生等具有显著炎症成分的疾病发病率增加有关。因此,了解调节这种谱系偏向转变的分子机制是众多人类疾病研究的一个重要领域。在这篇综述中,我们总结了目前对衰老过程中调节造血干细胞谱系命运偏向的细胞内在(自主)和细胞外在因素的理解。此外,我们试图提请注意与造血干细胞谱系偏向问题相关的重要注意事项和未解决的问题,以鼓励对这些重要研究方向进行探索。最终,我们期望全面了解衰老过程中的造血干细胞谱系偏向对人类健康具有重要意义,因为改变老年造血干细胞谱系偏向的策略不仅有可能恢复老年人的免疫功能,还能降低炎症相关疾病的发病率,其中许多疾病目前尚无新的更有效治疗方法。